News

Joyce A. O’Shaughnessy, MD, highlights multidisciplinary approaches including discussions on tumor boards, and discusses how to better assist patients with accessing care, and notable advances in the field particularly with the HER2 classification.

The FDA has extended the review period for a new drug application for quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, for the treatment of newly diagnosed adult patients with FLT3-ITD–positive acute myeloid leukemia.

A genome-wide methylome enrichment platform demonstrated efficacy in detecting early-stage, low-shedding cancers with limited circulating tumor DNA.

In pancreatic cancer, the role of the endoscopist continues to evolve as technologies like endoscopic ultrasound–guided biopsies present clinicians with increasingly accurate information to characterize the tumor microenvironments of individual patients and determine effective targeted therapies.

Looking to replicate the impressive findings with CAR T-cell therapies observed in patients with hematologic malignancies, investigators have initiated the BASECAMP-1 trial, with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in a subsequent trial evaluating the investigational agent A2B530.

University of Cincinnati Cancer Center researchers presented more than a dozen abstracts at the 2023 American Association for Cancer Research Annual Meeting, including findings that could advance treatments for head and neck and breast cancers.

The combination of the potentially first-in-class off-the-shelf therapeutic cancer vaccine candidate VB10.16 and atezolizumab elicited a median overall survival greater than 25 months in patients with PD-L1–positive, human papillomavirus 16–positive advanced cervical cancer.

Leaked data from an abstract scheduled to be presented at the 2023 EHA Hybrid Congress showed that ciltacabtagene autoleucel demonstrated a 74% reduction in the risk of disease progression or death compared with standard therapy in patients with relapsed/refractory multiple myeloma who received 1 to 3 prior lines of therapy.

To evaluate the prevalence of financial toxicity and observe the effect of Coverage and Cost-of-Care Links, a program providing financial navigation, investigators initiated a nonrandomized study.

The FDA has granted a fast track designation to the combination of botensilimab plus balstilimab for the treatment of patients with non–microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer with no active liver involvement.

Findings from a phase 1 study showed that the fully humanized IgG4 antibody IO-108 was well tolerated and displayed durable responses when given as a monotherapy as well as in combination with pembrolizumab, supporting further development of the agent alone or with PD-1/PD-L1 targeted therapy for patients with advanced solid tumors.

The FDA has approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone for use in adult patients who have previously untreated diffuse large B-cell lymphoma, not otherwise specified or high-grade B-cell lymphoma and who have an International Prognostic Index score of two or greater.

Adjuvant pembrolizumab prolonged disease-free survival and distant metastasis–free survival vs placebo in patients with clear cell renal cell carcinoma at increased risk of recurrence after nephrectomy, irrespective of UCLA Integrated Staging System risk category and disease stage.

RLY-2608 led to sustained target inhibition with minimal effect on glucose homeostasis, acceptable safety, and antitumor activity in patients with PIK3CA-mutant solid tumors, according to interim data from the dose-escalation portion of the first-in-human phase 1 ReDiscover trial.

April is Head and Neck Cancer Awareness Month, and a promising new research initiative at UC Davis Comprehensive Cancer Center could lead to a new and far more effective standard of care for this group of cancers.

An independent data monitoring committee has recommended that the phase 3 REGAL trial examining galinpepimut-S in patients with acute myeloid leukemia continue as planned without modifications.

A new genetic test that may allow patients with colorectal cancer to avoid chemotherapy after tumor resection is under investigation at AdventHealth Cancer Institute in Orlando, Florida.

Jane Lowe Meisel, MD, discusses previously reported data from the ELAINE-1 and ELAINE-2 trials, their significance within the ESR1-mutant, ER-positive, HER2-negative breast cancer treatment paradigm, and the purpose of the ongoing ELAINE-3 trial.

Although the phase 2 CYCLONE 1 trial did not meet its primary end point of overall response rate, treatment with abemaciclib did demonstrate clinical activity among patients with metastatic castration-resistant prostate cancer.

The combination of PARP and ATR inhibition with olaparib and ceralasertib was tolerable but showed limited efficacy in pediatric patients with advanced malignancies harboring DNA replication stress and DNA repair deficiencies, according to findings from arm N of the phase 1/2 AcSé-ESMART trial.

Pemigatinib generated efficacy and tolerability in previously treated patients with advanced/metastatic or unresectable solid tumors harboring activating FGFR mutations or fusions/rearrangements, including cholangiocarcinoma, central nervous system tumors, gynecologic tumors, and pancreatic cancer.

The FDA has accepted for priority review the supplemental new drug application seeking the approval of trifluridine/tipiracil as a single agent or in combination with bevacizumab for use in select patients with refractory, metastatic colorectal cancer.

Whole-exome sequencing successfully identified genetic conditions in patients who may have been missed by clinical guidelines.

A deep learning risk prediction model was able to accurately identify patients with endometrial cancer at low and high risk of distant recurrence, according to data presented during the 2023 AACR Annual Meeting.